ArticleArtificial organs2025
Clinical Results for Cardiovascular Xenografts Treated With Novel Anticalcification Protocols.
Article in Artificial organs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effective Recellularization Using Mesenchymal Stem Cell Monoculture for Next-Generation Heart Valves.Bioengineering (Basel, Switzerland) · 2026Article
- Enhanced Properties of Collagen Nanofiber Scaffolds via Chitosan/Polypyrrole/Glutaraldehyde Double-Crosslinking.Membranes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlutaraldehyde (GA) generates cross-links between cardiovascular xenografts to obtain tissue stability and attenuate antigenicity. However, the long-term durability of GA-fixed cardiovascular xenografts treated with previous anticalcification strategies has remained a challenge because tissue phospholipids, free aldehyde groups of GA, and residual antigenicity contribute to calcification. This study aimed to assess the safety, efficacy, and clinical performance of a bovine pericardial scaffold treated with our novel anticalcification protocols (Periborn) in patients with cardiovascular diseases.
methodsBovine pericardia were decellularized with 0.25% sodium dodecyl sulfate, 0.5% Triton X-100, and treated with a space-filler with polyethylene glycol. These tissues were cross-linked with 0.5% GA in a 75% ethanol +5% octanol organic solvent and treated with glycine for detoxification to produce Periborn. Between July 2015 and April 2022, 451 Periborn patches were implanted in 352 cases for cardiovascular surgeries.
resultsThe mean age at the time of surgery was 22.74 ± 20.09 years (13 days-89.5 years), follow-up duration was 4.25 ± 2.56 years (17 days-8.6 years), and no patch-related mortalities were observed. Five patients were reoperated owing to patch-related complications including decreased mobility, erosion, pseudoaneurysm, and calcification, and the overall probability of freedom from Periborn-related reoperation was 99.4% ± 0.4% at 1 year, 98.6% ± 0.7% at 5 years, and 95.4% ± 3.2% at 9 years.
conclusionsThis retrospective study demonstrates the safety and efficacy of the tissue-engineered Periborn bovine pericardial scaffold for the surgical repair of various cardiovascular diseases. The excellent durability and hemodynamic performance of Periborn make our novel anti-calcification protocol attractive and may require long-term follow-up to confirm durability and further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.